Five things for pharma marketers to know: Thursday, March 4, 2021
Health insurers launch program to vaccinate 2 million seniors; Studies show Brazil variant reinfected former COVID patients; Ovid Therapeutics sells soticlestat to Takeda.
Roundup
Five things for pharma marketers to know: Wednesday March 3, 2021
White House brokers Merck/J&J deal on vaccine production; Texas relaxes COVID mandates; Trump Administration diverted hospital funds to Operation Warp Speed.
Five things for pharma marketers to know: Tuesday, March 2, 2021
Johnson & Johnson vaccine to start being administered in next few days; Merck to acquire head and neck cancer therapy xevinapant; U.S. COVID-19 cases plateau at ‘very high number.’
Five things for pharma marketers to know: Monday, March 1, 2021
Mass vaccinations in Israel result in a drop of severe COVID-19 cases; Amgen’s tezepelumab shows success in PHASE III Navigator study; Cigna’s Evernorth acquires MDLive.
Five things for pharma marketers to know: Friday, February 26, 2021
U.S. administers 68 million vaccine doses; Sarepta’s Duchenne muscular dystrophy drug gains FDA approval; Merck acquires Pandion for $1.85 billion.
Five things for pharma marketers to know: Thursday, February 25, 2021
Moderna sends vaccine targeting COVID variants to NIH; FDA scientists endorse Johnson & Johnson vaccine; Biden administration to send 25 million masks to low-income communities.
Five things for pharma marketers to know: Wednesday, February 24, 2021
Pfizer and Moderna to double vaccine production; Latin American leaders accuse Pfizer of ‘bullying’ them over vaccine negotiations; Becerra appears before Senate confirmation hearing.
Five things for pharma marketers to know: Tuesday, February 23, 2021
U.S. reaches 500,000 COVID-19 deaths; FDA says vaccines targeting variants may be approved without clinical trials; Amgen plans to submit sNDA for Otezla.
Five things for pharma marketers to know: Monday, February 22, 2021
Pfizer asks to store vaccine at higher temperature; AstraZeneca/Oxford vaccine more effective with three-month interval between doses; AMR Action Fund hires new CEO.
Five things for pharma marketers to know: Friday, February 19, 2021
U.S. life expectancy declines by a full year; Biden picks Chiquita Brooks-LaSure to head CMS; Eli Lilly partners with Rigel on neurodegeneration therapy
Five things for pharma marketers to know: Thursday, February 18, 2021
Experts call on CDC to set workplace air standards; Johnson & Johnson may have limited vaccine supply at outset; Novartis and Gates Foundation collaborate on sickle cell disease therapy.
Five things for pharma marketers to know: Wednesday, February 17, 2021
Weekly vaccine doses to states and pharmacies surge; Bristol Myers Squibb and Sanofi to pay Hawaii $834 million for deceptive marketing; Former Operation Warp Speed chief launches pharma company.
Five things for pharma marketers to know: Tuesday, February 16, 2021
Biden administration plans to vaccinate 300 million by July; Takeda’s maribavir shows promise in Phase III trial; FDA struggles to gather vaccination safety data.
Five things for pharma marketers to know: Friday, February 12, 2021
Income-based vaccination disparities appear; Roche arthritis drug shows promise in reducing COVID-19 deaths; Novo Nordisk drug effectively treats obesity.
Five things for pharma marketers to know: Thursday, February 11, 2021
Industry groups push for ACA expansion; CDC recommends double-masking; Gilead and Galapagos halt IPF drug.
Want to read more?
Please login or register first to view this content.
